市場調查報告書

思覺失調症治療藥市場(各類藥物:第一代,第二代,第三代,給藥途徑:口服,注射):全球產業分析,規模,佔有率,成長,趨勢,預測(2019∼2027年)

Schizophrenia Drugs Market (Drug Class: First Generation Drugs, Second Generation Drugs, and Third Generation Drugs; Route of Administration: Oral and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版商 Transparency Market Research 商品編碼 920595
出版日期 內容資訊 英文 148 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
思覺失調症治療藥市場(各類藥物:第一代,第二代,第三代,給藥途徑:口服,注射):全球產業分析,規模,佔有率,成長,趨勢,預測(2019∼2027年) Schizophrenia Drugs Market (Drug Class: First Generation Drugs, Second Generation Drugs, and Third Generation Drugs; Route of Administration: Oral and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
出版日期: 2019年10月07日內容資訊: 英文 148 Pages
簡介

本報告提供思覺失調症治療藥市場相關調查,彙整市場趨勢與預測,市場規模,主要加入企業,各地區趨勢相關資訊。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
  • 概要
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
  • 市場分析與預測

第5章 主要趨勢

  • 開發平台分析
  • 價值鏈分析
  • 銷售額分析

第6章 市場分析與預測:各類藥物

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場收益預測
    • 第一代
    • 第二代
    • 第三代
  • 市場魅力度

第7章 市場分析與預測:各給藥途徑

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場收益預測
    • 注射
    • 口服
  • 市場魅力度

第8章 市場分析與預測:各地區

  • 主要調查結果
  • 市場收益預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力度

第9章 北美

第10章 歐洲

第11章 亞太地區

第12章 南美

第13章 中東·非洲

第14章 競爭環境

  • 市場佔有率分析
  • 企業簡介
目錄

Schizophrenia Drugs Market - Scope of the Report

TMR's report on the global schizophrenia drugs market studies the past as well as current growth trends and opportunities, and provides valuable insights of the same indicators for the said market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global schizophrenia drugs market for the period of 2017 to 2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global schizophrenia drugs market for the forecast period of 2019 to 2027.

The report has been prepared after extensive research. Primary research involved bulk of the research efforts, wherein, analysts conducted interviews with market leaders and opinion makers. Extensive secondary research involves studying key players' product literature, annual reports, press releases, and relevant documents to understand the schizophrenia drugs market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approach to study various phenomena in the schizophrenia drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the schizophrenia drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the schizophrenia drugs market.

The report delves into the competitive landscape of the schizophrenia drugs market. Key players operating in the global schizophrenia drugs market are identified, and each one of them are profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT analysis are some of the attributes of the players in the global schizophrenia drugs market profiled in this report.

Key Questions Answered in the Global Schizophrenia Drugs Market Report

How does the development of schizophrenia drugs provide scope of growth in the schizophrenia drugs market?

How are alliances and partnerships between players widening the scope of new lines of treatment for schizophrenia?

What are the revenue share projections of key segments under various criteria in the global schizophrenia drugs market during the forecast period?

Which segment is likely to register leading revenue until the end of the forecast period?

How is the evolving healthcare system in developing countries of Asia Pacific making an impact on the overall schizophrenia drugs market?

Global Schizophrenia Drugs Market - Research Objectives and Research Approach

The comprehensive report on the schizophrenia drugs market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, and healthcare compliances laid down by accredited agencies in the purview of the line of treatment of schizophrenia.

For reading comprehensibility, the report is compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of the key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global schizophrenia drugs market in terms of drug class, route of administration, and region. Key segments under each criteria are studied at length, and the market shares for each of them at the end of 2027 are provided herein. Such valuable insights enable market stakeholders in making informed business decisions for investment in the schizophrenia drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Schizophrenia Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Schizophrenia Drugs Introduction
    • 4.1.2. Market Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Schizophrenia Drugs Market Analysis and Forecast, 2017-2027
    • 4.4.1. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast

5. Key Insights

  • 5.1. Pipeline Analysis: Schizophrenia Drugs
  • 5.2. Value Chain Analysis
  • 5.3. Global Schizophrenia Drugs Sales Analysis, 2017-2027

6. Global Schizophrenia Drugs Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definitions
  • 6.2. Key Findings / Developments
  • 6.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 6.3.1. First Generation Drugs
    • 6.3.2. Second Generation Drugs
    • 6.3.3. Third Generation Drugs
  • 6.4. Global Schizophrenia Drugs Market Attractiveness, by Drug Class

7. Global Schizophrenia Drugs Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definitions
  • 7.2. Key Findings / Developments
  • 7.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
    • 7.3.1. Injectable
    • 7.3.2. Oral
  • 7.4. Global Schizophrenia Drugs Market Attractiveness, by Route of Administration

8. Global Schizophrenia Drugs Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Global Schizophrenia Drugs Market Attractiveness, by Region

9. North America Schizophrenia Drugs Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 9.2.1. First Generation Drugs
    • 9.2.2. Second Generation Drugs
    • 9.2.3. Third Generation Drugs
  • 9.3. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
    • 9.3.1. Injectable
    • 9.3.2. Oral
  • 9.4. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017-2027
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. North America Schizophrenia Drugs Market Attractiveness Analysis
    • 9.5.1. By Drug Class
    • 9.5.2. By Route of Administration
    • 9.5.3. By Country

10. Europe Schizophrenia Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 10.2.1. First Generation Drugs
    • 10.2.2. Second Generation Drugs
    • 10.2.3. Third Generation Drugs
  • 10.3. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
    • 10.3.1. Injectable
    • 10.3.2. Oral
  • 10.4. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Europe Schizophrenia Drugs Market Attractiveness Analysis
    • 10.5.1. By Drug Class
    • 10.5.2. By Route of Administration
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Schizophrenia Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 11.2.1. First Generation Drugs
    • 11.2.2. Second Generation Drugs
    • 11.2.3. Third Generation Drugs
  • 11.3. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
    • 11.3.1. Injectable
    • 11.3.2. Oral
  • 11.4. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 11.4.1. China
    • 11.4.2. India
    • 11.4.3. Japan
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis
    • 11.5.1. By Drug Class
    • 11.5.2. By Route of Administration
    • 11.5.3. By Country/Sub-region

12. Latin America Schizophrenia Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 12.2.1. First Generation Drugs
    • 12.2.2. Second Generation Drugs
    • 12.2.3. Third Generation Drugs
  • 12.3. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
    • 12.3.1. Injectable
    • 12.3.2. Oral
  • 12.4. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Latin America Schizophrenia Drugs Market Attractiveness Analysis
    • 12.5.1. By Drug Class
    • 12.5.2. By Route of Administration
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Schizophrenia Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 13.2.1. First Generation Drugs
    • 13.2.2. Second Generation Drugs
    • 13.2.3. Third Generation Drugs
  • 13.3. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
    • 13.3.1. Injectable
    • 13.3.2. Oral
  • 13.4. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 13.4.1. GCC
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis
    • 13.5.1. By Drug Class
    • 13.5.2. By Route of Administration
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Global Schizophrenia Drugs Market Share Analysis, by Company (2018)
  • 14.2. Company Profiles
    • 14.2.1. Allergan
      • 14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.2.1.2. Financial Overview
      • 14.2.1.3. Product Portfolio
      • 14.2.1.4. SWOT Analysis
      • 14.2.1.5. Strategic Overview
    • 14.2.2. Otsuka Holdings Co., Ltd
      • 14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.2.2.2. Financial Overview
      • 14.2.2.3. Product Portfolio
      • 14.2.2.4. SWOT Analysis
      • 14.2.2.5. Strategic Overview
    • 14.2.3. Janssen Pharmaceutica (Johnson & Johnson)
      • 14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.2.3.2. Financial Overview
      • 14.2.3.3. Product Portfolio
      • 14.2.3.4. SWOT Analysis
      • 14.2.3.5. Strategic Overview
    • 14.2.4. Pfizer Inc.
      • 14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.2.4.2. Financial Overview
      • 14.2.4.3. Product Portfolio
      • 14.2.4.4. SWOT Analysis
      • 14.2.4.5. Strategic Overview
    • 14.2.5. Maynepharma
      • 14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.2.5.2. Financial Overview
      • 14.2.5.3. Product Portfolio
      • 14.2.5.4. SWOT Analysis
      • 14.2.5.5. Strategic Overview
    • 14.2.6. Vanda Pharmaceuticals Inc.
      • 14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.2.6.2. Financial Overview
      • 14.2.6.3. Product Portfolio
      • 14.2.6.4. SWOT Analysis
      • 14.2.6.5. Strategic Overview
    • 14.2.7. Sumitomo Dainippon Pharma
      • 14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.2.7.2. Financial Overview
      • 14.2.7.3. Product Portfolio
      • 14.2.7.4. SWOT Analysis
      • 14.2.7.5. Strategic Overview
    • 14.2.8. Eli Lilly & Co.
      • 14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.2.8.2. Financial Overview
      • 14.2.8.3. Product Portfolio
      • 14.2.8.4. SWOT Analysis
      • 14.2.8.5. Strategic Overview
    • 14.2.9. AstraZeneca Plc
      • 14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.2.9.2. Financial Overview
      • 14.2.9.3. Product Portfolio
      • 14.2.9.4. SWOT Analysis
      • 14.2.9.5. Strategic Overview

List of Tables

  • Table 01: Pipeline Analysis
  • Table 02: Depression Drugs Sales Analysis, 2015-2017
  • Table 03: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 04: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 05: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region, 2017-2027
  • Table 06: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017-2027
  • Table 07: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 08: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 09: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 10: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 11: Europe Schizophrenia drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 12: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 13: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 14: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 15: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 16: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 17: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 18: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 19: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 20: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017-2027

List of Figures

  • Figure 01: Global Schizophrenia Drugs Market Analysis, by Route of Administration
  • Figure 02: Global Schizophrenia Drugs Market Analysis, by Drug Class
  • Figure 03: Global Schizophrenia Drugs Market Analysis, by Region
  • Figure 04: Global Schizophrenia Drugs Market Revenue (US$ Mn) and Distribution (%), by Region, 2018 and 2027
  • Figure 05: Global Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018
  • Figure 06: Global Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018
  • Figure 07: Global Schizophrenia Drugs Market Value Share Analysis, by Region, 2018
  • Figure 08: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, 2017-2027
  • Figure 09: Global Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 10: Global Schizophrenia Drugs Market Revenue (US$ Mn), by First Generation Drugs, 2017-2027
  • Figure 11: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Second Generation Drugs, 2017-2027
  • Figure 12: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Third Generation Drugs, 2017-2027
  • Figure 13: Global Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 14: Global Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 15: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Oral Route of Administration, 2017-2027
  • Figure 16: Global Schizophrenia Drugs Market Revenue (US$ Mn), by Injectable Route of Administration, 2017-2027
  • Figure 17: Global Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019-2027
  • Figure 18: Global Schizophrenia Drugs Market Value Share Analysis, by Region, 2018 and 2027
  • Figure 19: Global Schizophrenia Drugs Market Attractiveness Analysis, by Region, 2019-2027
  • Figure 20: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 21: North America Schizophrenia Drugs Market Attractiveness Analysis, by Country, 2019-2027
  • Figure 22: North America Schizophrenia Drugs Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 23: North America Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 24: North America Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 25: North America Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 26: North America Schizophrenia drugs Market Attractiveness Analysis, by Route of Administration, 2019-2027
  • Figure 27: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 28: Europe Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 29: Europe Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 30: Europe Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 31: Europe Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 32: Europe Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 33: Europe Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019-2027
  • Figure 34: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 35: Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 36: Asia Pacific Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 37: Asia Pacific Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 38: Asia Pacific Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 39: Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 40: Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019-2027
  • Figure 41: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 42: Latin America Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 43: Latin America Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 44: Latin America Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 45: Latin America Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 46: Latin America Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 47: Latin America Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019-2027
  • Figure 48: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 49: Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 50: Middle East & Africa Schizophrenia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 51: Middle East & Africa Schizophrenia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 52: Middle East & Africa Schizophrenia Drugs Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 53: Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 54: Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis, by Route of Administration, 2019-2027
  • Figure 55: Global Schizophrenia drugs Market Analysis, by Company Ranking, 2018
  • Figure 56: Johnson & Johnson Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015-2018
  • Figure 57: Johnson & Johnson R&D Expenses (US$ Mn) and Y-o-Y Growth (%) Projection, 2015-2018
  • Figure 58: Johnson & Johnson Breakdown of Net Sales, by Region, 2018
  • Figure 59: Johnson & Johnson Breakdown of Net Sales, by Business Segment, 2018
  • Figure 60: Allergan Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015-2018
  • Figure 61: Allergan R&D Expenses (US$ Mn) and Y-o-Y Growth (%) Projection, 2015-2018
  • Figure 62: Allergan Breakdown of Net Sales, by Business Segment (%), 2018
  • Figure 63: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2016-2018
  • Figure 64: Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018
  • Figure 65: Otsuka Holdings Co. Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2014-2017
  • Figure 66: Otsuka Holdings Co. Ltd. R&D Spending and Sales & Distribution Spending (US$ Bn) - Company Level, 2016-2017
  • Figure 67: Otsuka Holdings Co. Ltd. Breakdown of Net Sales, by Region (Company Level), 2017
  • Figure 68: Otsuka Holdings Co. Ltd. Breakdown of Net Sales (Overall Company Level), 2017
  • Figure 69: Eli Lily and Company Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2016-2018
  • Figure 70: Eli Lily and Company Breakdown of Net Sales, by Neuroscience Level, 2018
  • Figure 71: Eli Lily and Company Breakdown of Net Sales, by Region, 2018
  • Figure 72: AstraZeneca Plc. Revenue (US$ Bn) & Y-o-Y Growth (%) Projection, 2014-2017
  • Figure 73: AstraZeneca Plc. Breakdown of Net Sales, by Region, 2018
  • Figure 74: AstraZeneca Plc. Breakdown of Net Sales, by Region, 2018 (%)
  • Figure 75: Mayne Pharma Group Limited Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2016-2018
  • Figure 76: Mayne Pharma Group Limited Breakdown of Net Sales (%), by Region, 2018
  • Figure 77: Sumitomo Dainippon Pharma Co., Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015-2017
  • Figure 78: Sumitomo Dainippon Pharma Co., Ltd. Breakdown of Net Sales, by Business Segment, 2017
  • Figure 79: Sumitomo Dainippon Pharma Co., Ltd. Breakdown of Net Sales, by Region, 2017
  • Figure 80: Vanda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015-2017
Back to Top